Purpose: Temozolomide (TMZ) is an oral alkylating agent that produces methyl adducts at the 0.6 position of guanine. The methyl adducts are removed by the DNA repair enzyme AGAT. As demonstrated by in vitro studies, cisplatin (CDDP) is able to down-regulate the AGAT activity, suggesting that CDDP could enhance the antitumor activity of TMZ. We designed a randomized phase II study to evaluate and compare the activity and safety profile of the combination versus single-agent TMZ in patients with advanced melanoma. Results: Tumor responses (complete and partial responses) were seen in 16 patients (26%) in arm A and 19 patients (29%) in arm B. The median time to progression (TTP) was 3.8 months in arm A and 5.8 months in arm B. The median overall survival (OS) was 11.5 months in arm A and 12 months in arm B. The difference between treatment arms regarding objective response rates, TTP and OS were not statistically significant. Toxicity was comparable between the two arms for anemia, leukopenia, neutropenia, thrombocytopenia, fatigue, constipation and arthralgias/myalgias. There was significantly more grade 3 and 4 emesis in the combination arm. Conclusions: No clear benefit in terms of response rates, median TTP or OS was shown with the combination of TMZ + CDDP. Additionally, the combination was associated with higher incidence of grade 3 and 4 emesis.
Introduction
Malignant melanoma accounts for 2% of all cancers in the USA and Europe and its incidence is increasing [1] . Metastatic disease is incurable and median survival, at 6-9 months, is short. Systemic therapy with palliative intent is the mainstay of treatment.
Dacarbazine has become the standard chemotherapy for metastatic melanoma, with a response rate of $ 15% [2] .
Responses are usually partial and last only for a few months. Other agents are administered, including platinum analogues, vinca alkalloids, nitrosoureas and taxanes, but none has a better response rate than dacarbazine [2, 3] . Combination chemotherapy results in higher response rates but with increased toxicity and no prolongation of response duration or survival benefit [3 -5] .
Temozolomide (TMZ) is an oral imidazotetrazine with activity in advanced melanoma and primary brain tumors. TMZ and dacarbazine share the active intermediary 5-(3-methyltriazen-1-yl)imidazole-4-carboximide (MTIC). However, unlike dacarbazine, which requires metabolic activation, TMZ spontaneously converts to MTIC under physiological conditions [6] . It has high oral bioavailability [7] and extensive tissue distribution, including penetration through the bloodbrain barrier. This is of particular interest in metastatic melanoma, because brain metastases are a common cause of treatment failure, possibly because of poor central nervous system (CNS) penetration by conventional treatments [8 -10] .
A randomized phase III trial showed equivalent overall survival and toxicity with increased progression-free survival and better quality of life with TMZ [11] . In addition, there is evidence to indicate that patients treated successfully with TMZ have a lower incidence of intracranial disease relapse than those responding to dacarbazine. A retrospective study looked at 41 patients with advanced melanoma who had responded to their initial treatment. Of those treated with TMZ, 10% subsequently developed brain metastases compared with 43% of dacarbazine responders [12] .
In addition, TMZ produces methyl adducts at the O 6 position of guanine. The methyl adducts are removed by the DNA repair enzyme AGAT. As demonstrated by in vitro studies, cisplatin (CDDP) is able to down-regulate the AGAT activity, so enhancing the antitumor activity of TMZ [13, 14] . From previous phase I study the recommended doses of TMZ + CDDP were 200 mg/m 2 daily on days 1-5 and 75 mg/m 2 of CDDP on day 1, respectively, every 4 weeks [15] .
We designed a randomized phase II study to compare the activity and safety profile of single-agent TMZ with the combination of CDDP and TMZ.
Patients and methods
Patients who had proven advanced metastatic melanoma were eligible for the study provided they fulfilled the following criteria: no previous chemotherapy; full recovery from previous radiotherapy, adjuvant biologic therapy or surgery; measurable disease; age 18 years or older; adequate bone marrow reserve [absolute neutrophil count > _ 1500/ml, platelets > _ 100 000/ml, hemoglobulin > _ 10 g/dl, urea and serum creatinine <1.5Â the upper limit of laboratory normal (ULN)]; adequate hepatic function (total bilirubin <1.5Â ULN, aspartate aminotransferase <3Â ULN and alkaline phosphatase < _ 2Â ULN, unless disease was arising from bone); and adequate birth control measures. Patients with brain metastases were allowed to take part in the study if no prior CNS radiation had been administered.
Patients were excluded from the study if they were pregnant or nursing (pregnancy tests were performed within 24 h before starting the study drugs); if they had uncontrolled vomiting that would interfere with the administration of oral medications; or if they had clinically significant comorbidity that would interfere with the study evaluation. Prior treatment had to have been completed at least 4 weeks before administration of a study drug. Local ethics review committees approved the protocol. All patients gave written informed consent before randomization, according to institutional guidelines.
Treatment
Patients were randomized to receive either TMZ (group A) or the combination of TMZ and CDDP (group B 
Statistical methods
The primary objective of the study was to compare response rates of patients in the intention-to-treat (ITT) population who were assigned to either TMZ or CDDP + TMZ. Secondary objectives were to assess the time to progression (TTP), overall survival (OS) and toxicity for the two treatments. The sample size was chosen to allow a detection of a 25% difference between the two arms with an 80% power to detect this difference at the 5% level of significance.
TTP was calculated from the date of initiation of treatment to the first progression of the disease. However, patients who died due to diseaserelated factors without having previously documentation of disease progression were considered as an event at the estimation of TTP. Survival time was calculated from the date of initiation of treatment to the date of death or day of last follow-up.
Pearson's x 2 -test and Fisher's exact test [16] were applied to compare patients' characteristics, response and toxicity. The Kaplan-Meier method [17] was used to calculate TTP, median follow-up and OS curves, while the log-rank test was used to compare time to event distributions. Exact confidence intervals (CI) were used to determine the 95% upper and lower confidence limits of a response rate [18] . The analysis was made on an ITT basis.
Results

Patients
Between September 1999 and April 2002, 132 patients were enrolled. Of those 66 patients were randomized to receive TMZ and 66 to receive the combination. Five patients with missing medical records were excluded from the analysis (four from group A, one from group B). The remaining 127 patients (62 in the TMZ treatment group and 65 in the combination treatment group) made up the eligible patient population, defined as those patients with untreated advanced metastatic melanoma. Additionally, two patients (one from group A and one from group B) never started chemotherapy. Those two patients were included in the analysis according to the ITT basis, except for the toxicity and treatment characteristics ( Figure 1 ). Patient demographics were similar for each treatment group (Table 1) . There were no significant differences in sex (P = 0.64), performance status (WHO criteria) (P = 0.51), number of metastatic sites (P = 0.45) or disease site at baseline between the treatment groups. A significant difference was seen in age between the treatment groups. This was considered to be a random finding, as patients were not stratified by age at randomization. Additionally, we have performed a bivariate Cox regression analysis for OS and bivariate logistic regression for response in order to adjust for this difference. In both cases no significant differences were found between the two groups.
Response to treatment
The response rates to the two regimens are shown in Table 2 . Assessment of objective response in the ITT population showed that a complete response was achieved by 8% (95% CI 2.7% to 17.8%) of the TMZ-treated group (five of 62) and by 11% (95% CI 4.4% to 20.9) of the combination treated group (seven of 65). Of the patients who were assigned TMZ, 26% (95% CI 15.5% to 38.5) (16 of 62) showed an objective response to treatment compared with 29% (95% CI 18.6% to 41.8) (19 of 65) of those assigned TMZ + CDDP [P = 0.695; when adjusting for American Joint Commission on Cancer (AJCC) metastasis (M) classification, P = 0.321]. Rates of disease stabilization were similar between the two groups. In three patients, partial responses were seen in the brain (one in group A and two in group B).
Among the responding patients (complete and partial responders), median OS was 15.3 months in the TMZ treatment group and 17.3 months in the combination treatment group (P = 0.68; when adjusting for AJCC M classification, P = 0.2686).
Duration of response for both groups was 8 months (range 1.3-45+; 95% CI 5.6-10.3), for the TMZ group 5.7 months (range 1.3-45+; 95% CI 4.6-6.9) and for the combination group 9.4 months (range 2.1-36.3+; 95% CI 6.7-12.1) Figure 1 . Progress through the various stages of the trial. (P = 0.35; when adjusting for AJCC M classification, P = 0.0814). Five patients have so far not progressed (three from the TMZ group and two from the combination group). Out of the five patients that responded to chemotherapy and have not yet progressed, two had only soft tissue metastasis (one from group A and one from group B), one had only lymph nodes metastasis (group B) and two patients had both skin and lymph node metastases (both from group A). Seven patients in the TMZ-treated group were not evaluable for response, two due to early tumor death, one changed hospital, one discontinued due to toxicity, one withdrew consent, one never started chemotherapy and one for unknown reasons. Five patients in the combination-treated group were not evaluable for response, one due to change of hospital, one due to sudden death due to heart failure, one withdrew consent, one never started chemotherapy and one for unknown reasons.
TTP and OS
With a median follow up of 39.9 months in the TMZ-treated group (range 0.2 -47.1; 95% CI 35.0-49.9) and a median follow up of 37 months in the combination treated group (range 0.7-51; 95% CI 34.8 -39.2), in the ITT population the median OS was 11.5 months in patients assigned to TMZ (range 0.2-47.1+; 95% CI 7.6-15.4) compared with 12 months (range 0.7 -51+; 95% CI 8.2 -15.7) in patients assigned to the combination (P = 0.8980; when adjusting for AJCC M classification, P = 0.4696) (Figure 2) . Twenty-nine patients in the TMZ-treated group survived >12 months, as did 32 in the combination-treated group (P = 0.7). Nine of the 16 TMZ treatment responders survived >12 months, compared with 15 of the 19 combination treatment responders (P = 0.15). At the time we ceased collecting clinical data, 25% (four of 16) TMZ-treated patients remained alive, compared with 21% (four of 19) of combination-treated patients (P = 1.000). No imbalances were found among the number of patients that survived >12 months between the two groups (survived <12 months, P = 0.317; survived > _ 12 months, P = 0.081). In addition, no imbalances were found among the number of responders that survived >12 months between the two groups (survived <12 months, P = 0.576; survived > _ 12 months, P = 0.293), as well as the number of responders that were still alive at the time we ceased collecting data (responders that are still alive, P = 1.000; responders that died, P = 0.481).
The median TTP was 3.8 months (range 0.2-47.1; 95% CI 2.6-5) in the TMZ-treated group and 5.8 months (range 0.1-37+; 95% CI 3.9 -7.8) in the combination-treated group (P = 0.6032; when adjusting for AJCC M classification, P = 0.3337) (Figure 3) .
In univariate analysis, performance status, the history of adjuvant therapy and the presence of visceral metastases emerged as important determinants of TTP and OS. In multivariate Cox analysis, performance status and the presence of visceral metastases were identified as significant adverse prognostic factors for survival. Also, history of adjuvant therapy affected the hazard of disease progression (Table 3 
and 4).
Safety
Of the 127 patients randomized in the ITT population, one patient in the TMZ treatment group and one in the combination treatment group did not receive at least one dose of study medication because of receiving off-protocol treatment. The remaining 125 patients made up the safety population. A median of three and four cycles of treatment per patient was administered in TMZ and combination treatment group, respectively; for a total of 217 cycles of TMZ therapy and 267 cycles of combination therapy.
Treatment characteristics are shown in Table 5 . Both treatments were well tolerated, with most adverse events being mild to moderate in severity. The percentage of patients reporting grade 3 or 4 adverse events was similar. The only exception was the percentage of patients reporting nausea and vomiting, which was higher in the combination treatment group (P = 0.002).
The most frequent adverse events observed with TMZ therapy were nausea and vomiting (51%), thrombocytopenia (31%), anemia (17%), leucopenia (19%) and neutropenia (11%). In the combination-treated patients nausea and vomiting (53%), anemia (36%), leucopenia (44%), thrombocytopenia (31%) and neutropenia (20%) were most frequent (Table 6 ). There were few non-hematological grade 3 or 4 adverse events. The percentage of patients who discontinued the study because of adverse events was 3% of the TMZ-treated group and 4% of the combination-treated group. In the TMZ-treated group there was one sudden death due to cardiac condition, and one gastrointestinal bleeding in the absence of thrombocytopenia. In the combination-treated group, one patient had increased toxicity such as grade 4 thrombocytopenia, grade 2 nausea and vomiting, and fever fatigue allergic reaction, one patient had grade 4 nephrotoxicity, nausea and vomiting, and grade 2 diarrhea, and one had kidney dysfunction.
Discussion
Chemotherapy for advanced melanoma remains largely palliative, and survival after diagnosis is short. Numerous trials of single agents and combinations of chemotherapy have been performed, but dacarbazine still remains the standard regimen. TMZ is approved in the USA for treatment of refractory anaplastic astrocytoma; it is a prodrug that hydrolyzes to MTIC at physiological pH [19] . Its complete oral bioavailability and its ability to cross the blood-brain barrier [20] make it an attractive alternative to dacarbazine, which possesses neither of these properties. TMZ has shown activity against CNS metastases in melanoma and other malignancies [21] . This could be an advantage in melanoma, as CNS metastases are a frequent cause of death. In phase I and II trials with single-agent TMZ, overall response rates of 17% to 21% were achieved [7, 22] . Combining TMZ with other drugs in several phase II/III in melanoma has demonstrated satisfactory activity and tolerability with these regimens [1, [23] [24] [25] [26] .
The rationale for designing a phase II trial to compare single-agent TMZ with the combination of TMZ + CDDP was based on the potential for improved antitumor activity. Both TMZ and CDDP are active against melanoma, and target DNA with disparate mechanisms of cytotoxic action. TMZ produces methyl adducts at the O 6 position of guanine via the MTIC intermediate [6, [27] [28] [29] [30] , whereas CDDP produces DNA cross-links preferentially at the N 7 positions of guanine and adenine [31] . The methyl adducts produced by TMZ are removed by the DNA repair enzyme AGAT and TMZ activity correlates inversely with AGAT activity [29] [30] [31] [32] . Depletion of AGAT by the alkylthansferase inhibitors O 6 -methylguanine and O
6
-benzylguanine [32 -36] potentiates TMZ activity in vitro and in vivo, suggesting that AGAT activity confers resistance to the TMZ.
CDDP may affect AGAT activity. A dose-dependent inactivation of AGAT activity has been demonstrated in HeLa human cervical carcinoma cells exposed to CDDP [13] . The ability of CDDP to down-regulate AGAT is supported by the increased sensitivity of leukemia blasts to TMZ, with concurrent CDDP administration [13] . Simultaneous treatment of leukemia blasts with TMZ and non-cytotoxic concentrations of CDDP produces significantly greater growth inhibition than treatment with TMZ alone [14] . This preclinical evidence suggests that CDDP may enhance the antitumor activity of TMZ.
In this randomized phase II study, we failed to confirm superiority with the combination of TMZ and CDDP. No significant differences were seen in terms of response rates, TTP, OS or 1-year survival. This can be attributed to the small sample, size since the study was sufficiently powered for a difference of 25% in overall objective response rate in favor of the combination arm, while a difference of a 3% magnitude was observed. The overall objective response rates of 26% and 29% achieved in this study compare favorably with rates reported for single-agent TMZ (13% to 21%) [6, 10, 21] or single-agent CDDP (16%) [37] . A similar response 
rate has been demonstrated with dacarbazine plus CDDP [38, 39] . As we felt that the response rate was high in the TMZ arm, we retrospectively analyzed our patients according to the new AJCC M classification [40] and we found that there was a statistical significant difference between the two groups (M1a 43.5%, M1b 19.4%, M1c 37.1%; versus M1a 26.2%, M1b 13.8%, M1c 56.9%) (P = 0.039). This might explain our findings, since we did not stratify our patients at randomization according to site of metastases. Moreover, the population in this study has a high proportion of patients with one site of disease and a lower proportion with hepatic involvement. Additionally, in this study, the duration of response achieved with the combination of TMZ + CDDP and the OS in both groups seems to be better than that of either agent alone [7, 22, 38] .
As patients with brain metastases were included in our study, antitumor activity in the CNS was seen, including regression of brain metastases.
The demonstration of three partial responses in brain metastases in this study reconfirms the results of previous studies [22, 23, 41] and verifies the promising activity of TMZ as single agent or in combination with other active drugs. Responses in brain metastases have rarely been achieved with other chemotherapy agents. As it has already been reported by our group [23] and others [12, 42, 43] , few patients in this study developed CNS involvement, further suggesting that TMZ may prevent the occurrence of metastasis to the brain. In the current study only 16% of the TMZ-treated and 18% of the combination-treated patients developed CNS metastases with a median follow-up of 39.9 and 37 months, respectively.
Both regimens were also found to be safe and well tolerated, and adverse events were mild to moderate in the majority of patients. Myelosuppression, the predominant toxicity associated with TMZ therapy, was reversible an noncumulative. Nausea and vomiting was experienced by half of the patients in both groups, with significantly more grade 3 and 4 toxicity in the combination group. Three patients discontinued treatment due to toxicity and one sudden death due to cardiac condition was reported, but it is not clear whether it was treatment related. Therefore, TMZ can be safety combined with CDDP the doses used in this study based on the phase I data.
In conclusion, the combination of TMZ and CDDP is safe and effective in the treatment of metastatic melanoma with satisfactory duration of response, but did not prove to be superior to single-agent TMZ in terms of response rate, TTP or OS. The responses achieved in the brain and the small number of patients who developed CNS metastases after the completion of treatment justifies the use of TMZ in patients with brain metastases.
